A Study to Evaluate ALN-2232 in Participants With Obesity

← catalyst calendar

NCT07463846 · readout in 250 d

Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.

Phase

Phase 1/2

Status

Recruiting

Study type

Interventional

Design

Randomized · Triple · Treatment

Enrollment

156estimated

Sites

Country

Canada

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis

Date

Filed

Basis

What it is

Start

2026-03-02

actual

When the study began enrolling

Primary completion

2027-04-27

estimated

The date the last participant is measured for the primary outcome — the readout window

Study completion

2028-03-02

estimated

The whole study's end, after follow-up

First posted

2026-03-11

actual

When this record first appeared on the registry

Results posted

—

When the sponsor posted results to the registry

Record updated

2026-08-12

actual

The sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

Obesity

Interventions

Drug: ALN-2232
Drug: Placebo
Drug: Tirzepatide

Primary outcomes

what the primary-completion date above is the date OF

Part A: Frequency of Adverse Events (AEs)

measured Up to 12 months

Part B: Percent Change from Baseline in Body Weight

measured Baseline up to Month 6

Part C: Percent Change from Baseline in Body Weight

measured Baseline up to Month 6

Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed